Literature DB >> 19226654

Pharmacokinetics of pyrrole-imidazole polyamides after intravenous administration in rat.

Akiko Fukasawa1, Takahiko Aoyama, Takashi Nagashima, Noboru Fukuda, Takahiro Ueno, Hiroshi Sugiyama, Hiroki Nagase, Yoshiaki Matsumoto.   

Abstract

The pharmacokinetics of pyrrole (Py)-imidazole (Im) polyamides was studied in rats after the intravenous administration of these compounds. Py-Im polyamide (A) was composed of Ac-ImPyPy-ImPyPy-beta-Dp (beta: beta-alanine, Dp: N,N-dimethylaminopropylamide). Py-Im polyamide (B) was composed of Ac-PyIm-beta-ImIm-PyPy-beta-PyPy-beta-Dp. Py-Im polyamide (C) was composed of Ac-PyPy-beta-PyImPy-PyPyPy-beta-ImPy-beta-Dp. The molecular weight of Py-Im polyamide (A) was 1035.12, that of Py-Im polyamide (B) was 1422.51 and that of Py-Im polyamide (C) was 1665.78. After the intravenous injection of Py-Im polyamide (A) at 1.3, 2.0, 7.5 and 15.0 mg/kg, Py-Im polyamides (B) and (C) at 1.0, 2.0, 3.0 and 5.0 mg/kg, the average systemic clearance and the volume of distribution at the steady state obtained by a non-compartmental method were in the ranges of 4.6-6.4 ml/min/kg and 244-412 ml/kg, 8.9-10.3 ml/min/kg and 1990-4567 ml/kg, and 7.3-11.9 ml/min/kg and 407-667 ml/kg, respectively. Dose linearity of Py-Im polyamides was observed. The plasma concentration-time profiles after the intravenous administration of Py-Im polyamides (A) and (B) were fitted well by a two-compartment model. Py-Im polyamide (C) was observed at high concentrations in the lungs. The plasma concentration-time profiles after the intravenous administration of Py-Im polyamide (C) were described using a catenary two-compartment model. This model is useful for describing the time course after the administration of high-molecular-weight Py-Im polyamides. 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226654     DOI: 10.1002/bdd.648

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  5 in total

1.  Pyrrole-imidazole polyamide targeting transforming growth factor β1 ameliorates encapsulating peritoneal sclerosis.

Authors:  Kazuo Serie; Noboru Fukuda; Shigeki Nakai; Hiroyuki Matsuda; Takashi Maruyama; Yoshinobu Murayama; Sadao Omata
Journal:  Perit Dial Int       Date:  2012-01-03       Impact factor: 1.756

2.  Activity of a Py-Im polyamide targeted to the estrogen response element.

Authors:  Nicholas G Nickols; Jerzy O Szablowski; Amanda E Hargrove; Benjamin C Li; Jevgenij A Raskatov; Peter B Dervan
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

3.  Quantitation of pyrrole-imidazole polyamide in rat plasma by high-performance liquid chromatography coupled with UV detection.

Authors:  Tomonori Kamei; Takahiko Aoyama; Chihiro Tanaka; Takafumi Nagashima; Yukio Aoyama; Hiroyuki Hayashi; Hiroki Nagase; Takahiro Ueno; Noboru Fukuda; Yoshiaki Matsumoto
Journal:  J Biomed Biotechnol       Date:  2012-06-13

Review 4.  Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer.

Authors:  Daisuke Obinata; Kenichi Takayama; Satoru Takahashi; Satoshi Inoue
Journal:  Cancers (Basel)       Date:  2017-02-28       Impact factor: 6.639

5.  Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice.

Authors:  Timothy W Synold; Bixin Xi; Jun Wu; Yun Yen; Benjamin C Li; Fei Yang; John W Phillips; Nicholas G Nickols; Peter B Dervan
Journal:  Cancer Chemother Pharmacol       Date:  2012-08-21       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.